NSAID DOSE UNIT FORMULATIONS WITH H2-RECEPTOR ANTAGONISTS AND METHODS OF USE
The present invention generally relates to unit dosage forms of naproxen and H 2 -receptor antagonists, comprising an immediate-release formulation of naproxen; an immediate-release formulation of an H 2 -receptor antagonist, and a delayed-burst release formulation of an H 2 -receptor antagonist.
1 . A unit dosage form, comprising:
(a) an immediate-release famotidine formulation;
(b) an immediate-release naproxen formulation; and
(c) a delayed-burst release famotidine formulation comprising famotidine and a release-delaying agent.
2 . The unit dosage form of claim 1 , wherein:
(a) the immediate-release famotidine formulation comprises from about 10 mg to about 30 mg famotidine;
(b) the immediate-release naproxen formulation comprises from about 200 mg to about 600 mg naproxen; and
(c) the delayed-burst release famotidine formulation comprises from about 10 mg to about 80 mg of famotidine, and a release-delaying agent.
3 . The unit dosage form of claim 2 , wherein the amount of famotidine in the delayed-burst release famotidine formulation is about the same as the amount of famotidine in the immediate release famotidine formulation.
4 . The unit dosage form of claim 2 , wherein the delayed-burst release famotidine formulation and the immediate release famotidine formulation each comprise about 20 mgs famotidine.
5 . The unit dosage form of claim 2 , wherein the amount of famotidine in the delayed-burst release famotidine formulation is greater than then amount of famotidine in the immediate release famotidine formulation.
6 . The unit dosage form of claim 4 , wherein the amount of famotidine in the delayed-burst release famotidine formulation is about 1.2-fold to 4-fold greater than the amount of famotidine in the immediate release famotidine formulation.
7 . The unit dosage form of claim 4 , wherein the unit dosage form contains about 200-600 mg naproxen, about 10-30 mg famotidine in the immediate release famotidine formulation, and about 20-80 mg famotidine in the delayed-burst release famotidine formulation.
8 . The unit dosage form of claim 1 , wherein the delayed-burst release famotidine formulation has a burst duration of about 60 minutes or less.
9 . The unit dosage form of claim 7 , wherein the delayed-burst release famotidine formulation has a burst duration of about 30 minutes or less.
10 . The unit dosage form of claim 1 , wherein release from (a) and/or (b) occurs within about 30 minutes after administration.
11 . The unit dosage form of claim 1 , wherein the release interval between (a) and (c) is at least about 1 hour.
12 . The unit dosage form of claim 10 , wherein the release is about 4 hours.
13 . The unit dosage form of claim 1 , wherein the famotidine from (a) and/or (c) is effective to raise gastric pH above about 4.5 for at least 4 hours.
14 . The unit dosage form of claim 1 , wherein the delayed-burst release of the famotidine from (c) extends the period during which gastric pH is raised.
15 . The unit dosage form of claim 12 , wherein the gastric pH is raised to a level that remains below about pH 6.5.
16 . The unit dosage form of claim 1 , wherein the release-delaying agent is formulated for a fixed-time delayed release.
17 . The unit dosage form of claim 15 , wherein the delayed-burst release famotidine formulation releases famotidine through osmotic rupture.
18 . The unit dosage form of claim 15 , wherein the delayed-burst release famotidine formulation begins to release famotidine at least about 4 hours after administration to a subject.
19 . The unit dosage form of claim 1 , wherein the release-delaying agent comprises an enteric material.
20 . The unit dosage form of claim 18 , wherein the delayed-burst release famotidine formulation releases famotidine at or above a pH of about 6.0.
21 . The unit dosage form of claim 19 , wherein the famotidine from (a) raises gastric pH above about 3.5 and below about 6.0.
22 . The unit dosage form of claim 18 , wherein the enteric material allows release at or above a pH of about 5.5.
23 . The unit dosage form of claim 21 , wherein the famotidine from (a) raises gastric pH above about 3.5 and below about 5.5.
24 . The unit dosage form of claim 18 , wherein said enteric barrier comprises a material selected from the group consisting of cellulosic polymers, methacrylates, vinyl polymers and copolymers, and combinations thereof.
25 . The unit dosage form of claim 1 , wherein (a), (b) and/or (c) comprises one or more pharmaceutically acceptable excipients selected from the group consisting of sugars, soluble salts, colorants, fillers, disintegrants, glidants, anti-lacking agents, anti-static agents, and combinations thereof.
26 . The unit dosage form of claim 1 , for treating or preventing pain or inflammation in a subject.
27 . The unit dosage form of claim 1 , wherein the unit dosage form is administered twice a day.
28 . The unit dosage form of claim 1 , for reducing the risk of an adverse side-effect of an NSAID.
29 . A method for treating or preventing pain or inflammation in a subject, comprising administering a unit dosage form of claim 1 .
30 . The method of claim 29 , wherein the unit dosage form is administered twice a day.
31 . A method for manufacture of a unit dosage form, comprising
(a) preparing an immediate release formulation comprising about 200-600 mg naproxen;
(b) preparing an immediate release formulation comprising about 10-30 mg famotidine;
(c) preparing a delayed-burst release formulation comprising about 40-80 mg famotidine; and
(d) combining the formulations of steps (a), (b) and (c), thereby resulting in a unit dosage form.